Anti-MOG (Myelin Oligodendrocyte Glycoprotein)–Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star

Frederico Castelo Moura, Douglas Kazutoshi Sato, Carolina Medeiros Rimkus, Samira Luisa Apóstolos-Pereira, Luana Michelli de Oliveira, Claudia Costa Leite, Kazuo Fujihara, Mario Luiz Ribeiro Monteiro & Dagoberto Callegaro

To cite this article: Frederico Castelo Moura, Douglas Kazutoshi Sato, Carolina Medeiros Rimkus, Samira Luisa Apóstolos-Pereira, Luana Michelli de Oliveira, Claudia Costa Leite, Kazuo Fujihara, Mario Luiz Ribeiro Monteiro & Dagoberto Callegaro (2015): Anti-MOG (Myelin Oligodendrocyte Glycoprotein)-Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star, Neuro-Ophthalmology, DOI: 10.3109/01658107.2015.1084332

To link to this article: http://dx.doi.org/10.3109/01658107.2015.1084332

Published online: 10 Nov 2015.

Article views: 13
CASE REPORT

Anti-MOG (Myelin Oligodendrocyte Glycoprotein)–Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star

Frederico Castelo Moura1, Douglas Kazutoshi Sato2,3, Carolina Medeiros Rimkus4, Samira Luisa Apóstolos-Pereira2, Luana Michelli de Oliveira2, Claudia Costa Leite4, Kazuo Fujihara3, Mario Luiz Ribeiro Monteiro1, and Dagoberto Callegaro2

1Department of Ophthalmology, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil, 2Department of Neurology, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil, 3Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai, Japan, and 4Department of Radiology and Oncology, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil

ABSTRACT

A 44-year-old man presented with severe right visual loss. The right fundus examination showed marked optic disc oedema associated with partial macular star. Serological blood tests for infectious agents were all negative. Serum aquaporin-4 antibody was negative but anti-MOG (myelin oligodendrocyte glycoprotein) was positive. Magnetic resonance revealed extensive lesion in right optic nerve. There was no visual improvement after intravenous therapy. Patient had no further attacks after follow-up. Optic disc oedema with macular star is found in several infectious and non-inflammatory disorders, but it has not been reported in optic neuritis (ON) associated with autoantibodies to myelin oligodendrocyte glycoprotein (anti-MOG).

Keywords: Devic’s syndrome, macular star, multiple sclerosis, myelin oligodendrocyte glycoprotein antibody, optic neuritis

INTRODUCTION

Optic neuritis (ON) is a common manifestation of many inflammatory central nervous system disorders. Patients with atypical ON features with severe visual loss require an extensive evaluation.1 Among other aetiologies, severe ON can be the first manifestation of neuromyelitis optica spectrum disorders (NMOs) associated with antibodies against aquaporin-4 (anti-AQP4), but a considerable proportion of atypical ON remains negative to anti-AQP4.2 Recently, we reported patients with isolated ON with positivity to antibodies against myelin oligodendrocyte glycoprotein (anti-MOG). Orbital magnetic resonance imaging (MRI) and optical coherence tomography (OCT) findings suggest that anti-MOG+ cases usually have extensive optic nerve lesions on the MRI, but they usually have a better visual acuity recovery and less retinal loss than anti-AQP4+ ON cases.3 Optic disc oedema with macular star is found in several infectious (e.g., neuroretinitis) and non-infectious disorders (e.g., anterior ischaemic optic neuropathy), but macular star is usually absent in optic neuritis of patients with multiple sclerosis, and it has not been reported in anti-MOG+ ON cases. Herein, we present a patient with isolated unilateral severe ON with serum anti-MOG positivity associated with optic disc ischaemia and macular star.
CASE REPORT

A previously healthy 44-year-old man developed severe visual loss evolving to no light perception (NLP) in 3 days in his right eye (OD) associated with pain on the same side. He had no recent infection or vaccination history and family history was unremarkable. The right fundus examination showed marked optic disc oedema associated with discrete cotton wool spots, flame-shaped haemorrhages, and retinal exudates temporal to the optic disc forming a partial macular star (Figure 1A). Serological blood tests for infectious agents were all negative (including Bartonella, Lyme, and syphilis) and orbital magnetic resonance imaging (MRI) revealed an extensive lesion in the right optic nerve compatible with ON (Figure 1C and D). Cerebrospinal fluid (CSF) analysis showed mild pleocytosis (21/mm$^3$) and normal protein (32 mg/dL; reference: <40 mg/dL). After 10 days of intravenous high-dose methylprednisolone (IVMP) treatment, the patient showed remarkable improvement of optic nerve oedema (Figure 1B), but no visual recovery. Serum anti-AQP4 was negative, but anti-MOG was positive (end point titre = 1:2048) using a cell-based assay with transfected cells.

There were no further episodes of visual loss during one year and a half of follow-up. Visual acuity remained NLP in OD and 1.0 in left eye (OS). Optical coherence tomography examination showed marked peripapillary retinal nerve fibre layer (RNFL) loss in OD (mean RNFL thickness = 30 $\mu$m) and was normal in OS (mean RNFL thickness = 107 $\mu$m).

DISCUSSION

Unilateral optic disc oedema with macular star may appear in several diseases, including neuroretinitis, hypertensive retinopathy, non-inflammatory papilloedema, and anterior ischaemic optic neuropathy. Different aetiologies may share a common pathway leading to axoplasmic flow stasis and axonal swelling, associated with disruption of glial organization in hypoxic/ischaemic retinal tissue. In this case, severe inflammation and swelling of the optic nerve head may have promoted vascular changes of the optic disc leading to secondary ischaemic optic neuropathy and peripapillary retinal oedema, resulting in the formation of a macular star.

Anti-MOG is predominantly of immunoglobulin G1 (IgG1) subtype, and it has been reported to have ability to promote complement dependent...
cytotoxicity in vitro⁶ and induces significant changes in the cytoskeleton of cultured oligodendrocytes.⁷ We recently reported a remarkable elevation of myelin basic protein without glial fibrillary acidic protein detectable in the CSF of a patient with anti-MOG+ definitive NMO, suggesting myelin damage without astrocyte injury.⁸ In common, both cases had anti-MOG positivity at the first event without any previous manifestation to induce exposition of central nervous system (CNS) antigens promoting a bystander phenomenon to produce autoantibodies. Taken together, it is possible that glial alterations and release of inflammatory factors associated with anti-MOG might have contributed to optic nerve inflammation, but further experimental studies are required to confirm this hypothesis.

Although anti-MOG+ patients with ON usually have a good visual recovery after IVMP, it is known that not all patients recover well.⁹ Our patient received IVMP and oral prednisone after ruling out other possible aetiologies and detection of an extensive optic nerve lesion on the MRI. Unfortunately, there was no visual recovery, suggesting that in patients with extensive ON, severe optic disc oedema associated with retinal swelling and macular star formation as seen in non-retrolubar ON may be signs of poor prognosis. Furthermore, this case emphasizes that the presence of severe disc oedema with macular star formation should not exclude severe ON, and prompt diagnosis and aggressive treatment during the acute phase might increase the chances of visual recovery.

Declaration of interest: The authors have the right to publish any and all data separate and apart from any sponsor. Drs. Moura, Apostolos-Pereira, de Oliveira, Leite, and Callegaro report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

This study was partially supported by KAKENHI (22229008) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, grant-in-aid for scientific research from the Japan Society for the Promotion of Science (KAKENHI 15K19472), and by the Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan. Dr. Sato has received scholarship from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, grant-in-aid for scientific research from the Japan Society for the Promotion of Science (KAKENHI 15K19472), research support from CAPES/Brazil, and speaker honoraria from Novartis. Dr. Rimkus receives research grant from FAPESP (2014/02010-6). Dr. Fujihara serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, Merck Serono, Alexion Pharmaceuticals, Medimmune, and Medical Review; has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec, Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Asahi Kasei Medical Co., Daiichi Sankyo, and Nihon Pharmaceutical; serves as an editorial board member of Clinical and Experimental Neurommunology (2009–present) and a advisory board member of Sri Lanka Journal of Neurology; has received research support from Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, and Genzyme Japan; is funded as the secondary investigator (no. 22229008, 2010–2015) by the Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology of Japan and as the secondary investigator by the Grants-in-Aid for Scientific Research from the Ministry of Health, Welfare and Labor of Japan (2010–present). Dr. Monteiro receives research funding from CNPq (307393/2014-3).

REFERENCES


